Please login to the form below

Not currently logged in
Email:
Password:

Isentress

This page shows the latest Isentress news and features for those working in and with pharma, biotech and healthcare.

MSD claims EU approval for two HIV products

MSD claims EU approval for two HIV products

Isentress is used as an add-on therapy to other HIV drugs and brought in $1.2bn in sales last year, but has started to be squeezed by new products from ... At the time, GlobalData analyst Thomas Moore said that while the two drugs are “unlikely to

Latest news

  • A new option for people with HIV A new option for people with HIV

    Other integrase inhibitors. Raltegravir ( Isentress; Merck) was the first integrase inhibitor to be approved by the US FDA in October 2007. ... tenofovir disoproxil fumarate (Atripla) and raltegravir (Isentress).

  • FDA clears Isentress formulation for infants with HIV FDA clears Isentress formulation for infants with HIV

    A new formulation of Merck &Co's drug Isentress has been cleared in the US to treat infants and children with HIV infection. ... By expanding the potential audience of Isentress, Merck will hope it can keep up in an increasingly competitive market for

  • ViiV's Tivicay for HIV on course for EU approval ViiV's Tivicay for HIV on course for EU approval

    Tivicay is the third entrant in the integrase inhibitor class after Merck &Co's Isentress (raltegravir) - which was first approved in 2007 - and Gilead Sciences' elvitegravir which was approved last year ... As the first entrant, Isentress is enjoying

  • ViiV gets US nod for HIV drug dolutegravir ViiV gets US nod for HIV drug dolutegravir

    a twice-daily treatment with rival integrase inhibitor Isentress (raltegravir) from Merck &Co and found they were equivalent in previously-untreated HIV patients. ... The SAILING study found that Tivicay was more effective than Isentress in suppressing

  • Merck profit slides as generics continue to bite Merck profit slides as generics continue to bite

    HIV drug Isentress (raltegravir) climbed 5 per cent to $410m, holding up fairly well despite increased competition from the likes of Gilead Sciences' elvitegravir, while sales of cholesterol drugs Zetia (ezetimibe)

More from news
Approximately 1 fully matching, plus 21 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Market Access Transformation

Market Access Transformation (MAT), founded by industry veterans Baiju Aurora and Paul Howard, specializes in developing cutting edge technologies that...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics